- In April 2024, Revvity introduced a next-generation sequencing-based panel and workflow for newborn screening, aiming to enhance current screening programs that predominantly rely on biochemical testing, thereby positioning itself to significantly impact the market by offering more comprehensive and accurate diagnostic capabilities
- In December, Revvity launched its EONIS Q system, a CE-IVD declared platform that allows laboratories in countries accepting the CE marking to integrate molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns, potentially expanding the adoption of advanced molecular diagnostics and advancing the market for genetic newborn screening
- In September 2020, PerkinElmer, Inc., a worldwide company devoted to developing for a healthy society, has gained CE-IVD certification for their EONISTM newborn screening assay, which screens for SMA (spinal muscular atrophy), SCID (severe combined immunodeficiency), and XLA (X-linked agammaglobulinemia). This IVD RT-PCR assay is designed to interact with PerkinElmer's full newborn screening workflow, giving labs a complete, single-source solution that includes everything from sample to solution
